ClinicalTrials.gg

Program

mitiglinide

Also written as “Mitiglinide”, “KAD-1229” and “mitiglinide and metformin”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, led by 4 companies.

Furthest: phase 4, since May 30, 20147 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kissei Pharmaceutical30 open or runningphase 4since May 30, 2014Apr 17, 2007none ahead
JW Pharmaceutical20 open or runningphase 4since Apr 18, 2008Apr 18, 2008none ahead
Elixir Pharmaceuticals10 open or runningphase 3since Aug 20, 2007Aug 20, 2007none ahead
Orient Europharma10 open or runningphase 4since Mar 3, 2020Mar 3, 2020none ahead

Also a collaborator on its studies: parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 17, 2007First study: phase 3 study in Diabetes MellitusNew to Kissei PharmaceuticalKissei Pharmaceutical · NCT00461617 · 291 enrolled
  2. Aug 20, 2007Elixir Pharmaceuticals's first study: phase 3 study in Diabetes Mellitus, Type 2New to Elixir PharmaceuticalsElixir Pharmaceuticals · NCT00519142 · 367 enrolled · United States, Puerto Rico
  3. Apr 18, 2008JW Pharmaceutical's first study: phase 4 study in Diabetes Mellitus, Type 2New to JW PharmaceuticalJW Pharmaceutical · NCT00663884 · 167 enrolled · Korea, Republic of
  4. Apr 6, 2011Phase 3 study in Diabetes Mellitus, Type 2Kissei Pharmaceutical · NCT01333592 · 136 enrolled · Japan
  5. Sep 27, 2011Phase 1 study in HealthyJW Pharmaceutical · NCT01443221 · 24 enrolled · Korea, Republic of
  6. May 30, 2014Phase 4 study in Diabetes Mellitus, Type 2Kissei Pharmaceutical · NCT02154347 · 178 enrolled · Japan
  7. Mar 3, 2020Orient Europharma's first study: phase 4 study in Diabetes Mellitus, Type 2New to Orient EuropharmaOrient Europharma · NCT04349696 · 16 enrolled · Taiwan

TargetBeta

“Sulfonylurea receptor 1, Kir6.2 blocker”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
repaglinideruleNovo Nordiskphase 432

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT04349696Diabetes Mellitus, Type 2 · Taiwan4CompletedOrient EuropharmaApr 201816
NCT02154347Diabetes Mellitus, Type 2 · Japan4CompletedKissei PharmaceuticalJul 2016178
NCT01443221Healthy · Korea, Republic of1CompletedJW PharmaceuticalJan 201124
NCT01333592Diabetes Mellitus, Type 2 · Japan3CompletedKissei PharmaceuticalAug 2012136
NCT00663884Diabetes Mellitus, Type 2 · Korea, Republic of4CompletedJW PharmaceuticalJul 2009167
NCT00519142Diabetes Mellitus, Type 2 · United States, Puerto Rico3CompletedElixir PharmaceuticalsOct 2008367
NCT00461617Diabetes Mellitus3CompletedKissei PharmaceuticalJul 2007291

How it is read

Names in the registry

  • “Mitiglinide”, 4 entries
  • “KAD-1229”, 2 entries
  • “mitiglinide and metformin”, 2 entries
  • “mitiglinide”, 2 entries
  • “Mitiglinide calcium hydrate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.